Opinion|Videos|June 6, 2024
Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis
Author(s)Lawrence Eichenfield, MD
In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.
Advertisement
Episodes in this series
- In your experience, what are the most commonly cited reasons by healthcare providers for switching treatments in patients with AD?
- In your experience, how might these factors vary across different stages of the disease or patient populations?
- How do you interpret the implications of the majority of patients experiencing improved disease control upon transitioning to ruxolitinib cream, particularly concerning disease management strategies and patient outcomes?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5
